Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease - Archive ouverte HAL Access content directly
Journal Articles npj Parkinson's Disease Year : 2021

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

(1) , (2, 3) , , (3) , (4) , , , , , , , , , , , , , , , (3)
1
2
3
4

Abstract

With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.
Fichier principal
Vignette du fichier
Oliveira et al npj Parkinson Dis 2021.pdf (1.36 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

cea-03308380 , version 1 (29-07-2021)

Identifiers

Cite

Luis M A Oliveira, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, et al.. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. npj Parkinson's Disease, 2021, 7, ⟨10.1038/s41531-021-00203-9⟩. ⟨cea-03308380⟩
120 View
34 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More